Explore the latest advancements in treating relapsed and refractory myeloma, including innovative therapies and their real-world applications.
Back
Integrating BCMA Directed Bispecifics into the Relapsed / Refractory Myeloma Landscape
In this OncLive® Insights program, Paul Richardson, MD, is joined by Hans Lee, MD, to examine the evolving role of BCMA-directed bispecific antibodies in the treatment of relapsed or refractory multiple myeloma. The discussion focuses on patients who are triple-class exposed or refractory and face limited options with conventional therapies. Drs Richardson and Lee review the biologic rationale for targeting BCMA, compare available therapeutic platforms including CAR T-cell therapy, antibody-drug conjugates, and bispecific antibodies, and explore how these approaches are being sequenced in real-world practice. The experts highlight linvoseltamab, including key design elements and outcomes from the LINKER-MM1 trial, safety considerations such as cytokine release syndrome and infection risk, and practical aspects of step-up dosing and treatment de-escalation. The conversation also highlights challenges and opportunities in community oncology settings, offering practical insights into integrating BCMA-directed bispecifics into everyday clinical care.
Integrating BCMA Directed Bispecifics into the Relapsed / Refractory Myeloma Landscape
Episodes
All
All
Exploring the complexities of treating refractory myeloma patients, highlighting the significance of BCMA as a therapeutic target and innovative treatment options.
Drs Paul Richardson and Hans Lee walk through the pivotal LINKER-MM1 trial that supported the July 2025 approval of linvoseltamab for patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy.
Drs Paul Richardson and Hans Lee focus on the safety profile of linvoseltamab and how its clinical features translate into real-world and community-based practice.
Drs Paul Richardson and Hans Lee focus on practical infection mitigation strategies for patients receiving BCMA-directed bispecific antibodies, with particular emphasis on the proactive use of intravenous immunoglobulin.
Drs Paul Richardson and Hans Lee compare the three currently available BCMA-directed bispecific antibodies and discuss how differences in administration, logistics, and emerging data influence treatment selection in relapsed or refractory multiple myeloma.
Drs Paul Richardson and Hans Lee address real-world strategies for managing cytokine release syndrome and how these considerations intersect with evolving treatment sequencing in multiple myeloma.
Drs Paul Richardson and Hans Lee discuss the evolving and often complex decisions around sequencing BCMA-directed therapies in multiple myeloma.
In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5